Home / Deep Research / Farber Disease

Farber Disease

Farber Disease Deep Research Fallback

⚠️ Fallback MONDO:0009218

Farber Disease Deep Research Fallback

Provider Attempts

  • 2026-05-05T11:20Z: just research-disorder falcon Farber_Disease produced no artifact after an extended silent wait and was interrupted.
  • 2026-05-05T11:31Z: just research-disorder openai Farber_Disease produced no artifact after a bounded silent wait and was interrupted.

No provider-generated deep-research narrative was available within the bounded runtime. Curation therefore proceeded from generated structured Orphanet evidence and fetched PubMed/ClinicalTrials.gov caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

  • ORPHA:333 structured record for disease definition, exact MONDO/OMIM mapping, ASAH1 disease-gene association, autosomal recessive inheritance, worldwide point prevalence, onset bands, and HPO phenotype frequencies.
  • PMID:29048419 for the cross-sectional natural-history cohort framing Farber disease as an ultra-rare progressive multisystem disorder with infancy onset.
  • PMID:30029679, PMID:36830643, and PMID:32449975 for clinical-spectrum review, ASAH1 acid ceramidase deficiency, classical triad, phenotype variability, and molecularly confirmed natural-history cases.
  • PMID:23707712 and PMID:29692406 for the molecular basis of ASAH1 loss of function and acid ceramidase enzymatic function.
  • PMID:31835809 and PMID:27915031 for lysosomal ceramide accumulation, lipid-laden macrophage granulomas, inflammatory cytokine/ceramide biomarkers, and Farber disease versus juvenile idiopathic arthritis differentiation.
  • PMID:28342444 and PMID:35902747 for CNS and retinal model mechanisms.
  • PMID:23881344 and PMID:28275553 for HSCT and recombinant acid ceramidase enzyme replacement evidence.
  • ClinicalTrials.gov NCT03233841 and NCT02298634 for natural-history and blood biomarker study context.

Curation Conclusions

Farber disease is an autosomal recessive ASAH1 acid ceramidase deficiency. Reduced N-acylsphingosine amidohydrolase activity blocks lysosomal ceramide catabolism, causing ceramide storage, macrophage-rich granulomatous lesions, and inflammatory cytokine/ceramide plasma abnormalities. The clinical signature is the classic triad of periarticular/subcutaneous nodules, painful swollen or contractured joints, and hoarse voice, with variable neurologic, respiratory, visceral, skeletal, and ocular involvement. Diagnosis is supported by deficient acid ceramidase activity, ASAH1 molecular testing, ceramide/biomarker assays, and awareness of juvenile idiopathic arthritis misdiagnosis. Treatment remains largely symptom directed; HSCT can improve selected non-neurologic features but has important limitations, while recombinant acid ceramidase ERT and AAV-ASAH1 retinal gene therapy remain investigational/preclinical in the cited evidence.